Why Drugmakers Are Paying for Free Cancer Gene Tests

Lung cancer patients in India now get free access to next-generation sequencing through the LuNGS Alliance, a collaboration of diagnostic labs, hospitals, and three of the world's largest drugmakers. The goal is to remove the cost barrier that keeps most patients from identifying the mutations targeted therapies attack.

Roche, AstraZeneca, and Pfizer fund the testing. They compete for the same lung cancer drug market. Yet all three agreed to share the cost of a common diagnostic platform. The alliance's governance keeps testing and treatment decisions separate, so no single company steers patients toward its own drug.

The model rests on volume. By pooling samples from multiple hospitals, the group negotiates lower per-test pricing from sequencing providers. Drugmakers benefit because more testing expands the pool of patients eligible for their drugs. The labs get consistent throughput. The patient pays nothing.

Early results show the approach works. In the first year, the alliance tested more than 5,000 patients. About 40% carried a mutation that matched an approved targeted therapy. Those patients were then directed to treatment, often through the same alliance's patient-assistance programs.

Lung cancer is the leading cause of cancer death in India. Most patients are diagnosed late, when surgery is no longer an option. Targeted therapies work only if the tumor has a specific mutation, which NGS can identify. Without the test, doctors default to chemotherapy, even when a more effective targeted drug exists.

The alliance is now studying whether the same model can work for breast and colorectal cancers. The sequencing technology already handles those tumor types. Talks are underway with diagnostic chains in smaller Indian cities to push coverage beyond the initial hospital network.

For investors, the implications are straightforward. More testing means a larger addressable market for targeted therapies in a country with 1.4 billion people. Lung cancer kills more Indians than any other cancer. If the alliance scales, it could shift the revenue trajectory for Roche, AstraZeneca, and Pfizer in Asia.

The catch is whether the volume game can outrun India's fragmented healthcare system. Centralized testing is difficult when patients are spread across thousands of small towns. The alliance's early success at major hospitals doesn't guarantee the same reach in rural clinics. The next year will show whether the model is repeatable or just a proof of concept.

Either way, the LuNGS Alliance has already demonstrated something rare: competing drugmakers funding a shared diagnostic infrastructure. That alone makes it worth watching.